Search Results

There are 17110 results for: content related to: Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

  1. Bortezomib for the treatment of multiple myeloma

    Intervention Review

    The Cochrane Library

    Kathleen Scott, Patrick J Hayden, Andrea Will, Keith Wheatley and Imelda Coyne

    Published Online : 20 APR 2016, DOI: 10.1002/14651858.CD010816.pub2

  2. You have free access to this content
    Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: 314–319, María Victoria Mateos, Paul G. Richardson, Meletios A. Dimopoulos, Antonio Palumbo, Kenneth C. Anderson, Hongliang Shi, Jennifer Elliott, Edward Dow, Helgi van de Velde, Liviu Niculescu and Jesús F. San Miguel

    Version of Record online : 27 FEB 2015, DOI: 10.1002/ajh.23933

  3. Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

    Journal of Periodontal Research

    Volume 50, Issue 2, April 2015, Pages: 248–255, J. Kitagaki, S. Miyauchi, C. J Xie, M. Yamashita, S. Yamada, M. Kitamura and S. Murakami

    Version of Record online : 20 JUN 2014, DOI: 10.1111/jre.12202

  4. You have free access to this content
    Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

    BJU International

    Volume 109, Issue 8, April 2012, Pages: 1258–1268, Akinori Sato, Takako Asano, Keiichi Ito, Makoto Sumitomo and Tomohiko Asano

    Version of Record online : 2 SEP 2011, DOI: 10.1111/j.1464-410X.2011.10533.x

  5. You have full text access to this Open Access content
    Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1

    Cancer Science

    Volume 100, Issue 2, February 2009, Pages: 341–348, Masaki Ri, Shinsuke Iida, Takashi Ishida, Asahi Ito, Hiroki Yano, Atsushi Inagaki, Jianmin Ding, Shigeru Kusumoto, Hirokazu Komatsu, Atae Utsunomiya and Ryuzo Ueda

    Version of Record online : 5 DEC 2008, DOI: 10.1111/j.1349-7006.2008.01038.x

  6. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

    Molecular Carcinogenesis

    Volume 52, Issue 2, February 2013, Pages: 118–133, Daniel R. Premkumar, Esther P. Jane, Naomi R. Agostino, Joseph D. DiDomenico and Ian F. Pollack

    Version of Record online : 15 NOV 2011, DOI: 10.1002/mc.21835

  7. You have free access to this content
    Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: E60–E65, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Despina Kalapanida, Constantinos Pamboucas, Elisavet Kaldara, Argyrios Ntalianis, Erasmia Psimenou, Savvas T. Toumanidis, Anna Tasidou, Evangelos Terpos and Meletios A. Dimopoulos

    Version of Record online : 9 MAR 2015, DOI: 10.1002/ajh.23936

  8. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma

    British Journal of Haematology

    Volume 168, Issue 1, January 2015, Pages: 55–62, Michelle Furtado, Rod Johnson, Anton Kruger, Deborah Turner and Simon Rule

    Version of Record online : 22 AUG 2014, DOI: 10.1111/bjh.13101

  9. Bortezomib use in a pediatric cardiac transplant center

    Pediatric Transplantation

    Volume 18, Issue 5, August 2014, Pages: 469–476, Matthew D. Zinn, Thomas J. L'Ecuyer, Omar R. Fagoaga and Sanjeev Aggarwal

    Version of Record online : 14 JUN 2014, DOI: 10.1111/petr.12300

  10. You have free access to this content
    Proteasome inhibition aggravates tumor necrosis factor–mediated bone resorption in a mouse model of inflammatory arthritis

    Arthritis & Rheumatism

    Volume 63, Issue 3, March 2011, Pages: 670–680, Karin Polzer, Kirsten Neubert, Silke Meister, Benjamin Frey, Wolfgang Baum, Jörg H. Distler, Eva Gückel, Georg Schett, Reinhard E. Voll and Jochen Zwerina

    Version of Record online : 25 FEB 2011, DOI: 10.1002/art.30177

  11. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines

    International Journal of Laboratory Hematology

    Volume 34, Issue 3, June 2012, Pages: 237–247, B. ZHENG, R. ZHOU, Y. GONG, X. YANG and Q. SHAN

    Version of Record online : 7 DEC 2011, DOI: 10.1111/j.1751-553X.2011.01384.x

  12. You have full text access to this Open Access content
    Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

    Cancer Science

    Volume 101, Issue 6, June 2010, Pages: 1403–1408, Daisuke Tamura, Tokuzo Arao, Kaoru Tanaka, Hiroyasu Kaneda, Kazuko Matsumoto, Kanae Kudo, Keiichi Aomatsu, Yoshihiko Fujita, Takashi Watanabe, Nagahiro Saijo, Yoshikazu Kotani, Yoshihiro Nishimura and Kazuto Nishio

    Version of Record online : 15 MAR 2010, DOI: 10.1111/j.1349-7006.2010.01544.x

  13. You have free access to this content
    Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells

    International Journal of Cancer

    Volume 133, Issue 6, 15 September 2013, Pages: 1357–1367, I.S. Song, H.K. Kim, S.R. Lee, S.H. Jeong, N. Kim, K.S. Ko, B.D. Rhee and J. Han

    Version of Record online : 4 APR 2013, DOI: 10.1002/ijc.28149

  14. You have free access to this content
    Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells

    International Journal of Urology

    Volume 19, Issue 6, June 2012, Pages: 565–574, Konstantinos Tsapakidis, Panagiotis J Vlachostergios, Ioannis A Voutsadakis, Christina D Befani, Anna Patrikidou, Eleana Hatzidaki, Danai D Daliani, George Moutzouris, Panagiotis Liakos and Christos N Papandreou

    Version of Record online : 10 FEB 2012, DOI: 10.1111/j.1442-2042.2012.02967.x

  15. Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy

    Glia

    Volume 58, Issue 16, December 2010, Pages: 1961–1976, Yoon Kyung Shin, So Young Jang, Hyun Kyoung Lee, Junyang Jung, Duk Joon Suh, Su-Yeong Seo and Hwan Tae Park

    Version of Record online : 9 SEP 2010, DOI: 10.1002/glia.21065

  16. You have free access to this content
    Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

    British Journal of Haematology

    Volume 143, Issue 2, October 2008, Pages: 222–229, Sagar Lonial, Paul G Richardson, Jesús San Miguel, Pieter Sonneveld, Michael W Schuster, Joan Bladé, Jamie Cavenagh, S. Vincent Rajkumar, Andrzej J Jakubowiak, Dixie-Lee Esseltine, Kenneth C Anderson and Jean-Luc Harousseau

    Version of Record online : 18 AUG 2008, DOI: 10.1111/j.1365-2141.2008.07321.x

  17. You have free access to this content
    The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer

    International Journal of Cancer

    Volume 137, Issue 3, 1 August 2015, Pages: 686–697, Sonja Thaler, Gitta Thiede, Jan G. Hengstler, Arno Schad, Marcus Schmidt and Jonathan P. Sleeman

    Version of Record online : 8 JAN 2015, DOI: 10.1002/ijc.29404

  18. You have free access to this content
    Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies

    Cancer

    Volume 104, Issue 9, 1 November 2005, Pages: 1794–1807, Heinz Ludwig, David Khayat, Giuseppe Giaccone and Thierry Facon

    Version of Record online : 21 SEP 2005, DOI: 10.1002/cncr.21414

  19. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer

    Journal of Surgical Oncology

    Volume 105, Issue 4, 15 March 2012, Pages: 357–364, Annette Wunderlich, Tjadina Arndt, Melina Fischer, Silvia Roth, Annette Ramaswamy, Brandon H. Greene, Cornelia Brendel, Ulrike Hinterseher, Detlef K. Bartsch and Sebastian Hoffmann

    Version of Record online : 17 OCT 2011, DOI: 10.1002/jso.22113

  20. Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer

    HPB

    Volume 11, Issue 7, November 2009, Pages: 600–605, Niranjan Awasthi, Margaret A. Schwarz and Roderich E. Schwarz

    Version of Record online : 13 OCT 2009, DOI: 10.1111/j.1477-2574.2009.00109.x